With the help of Duane Morris partner Driscoll Ugarte, a New Jersey biopharmaceutical company will leap forward with its final phase of development for a new drug for cancer patients suffering from one of the most common side effects of treatment.
The Boca Raton attorney represented Soligenix Inc., which focuses on developing and commercializing drugs that treat rare diseases, in a $3 million deal with SciClone Pharmaceuticals Inc., a Foster City, California-based company that plans to introduce the treatment in Asia.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
